Jiang Yuqian, Lian Xiaojun Lance
Department of Biomedical Engineering, Pennsylvania State University, University Park, PA, 16802, USA.
Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, PA, 16802, USA.
Bioact Mater. 2020 Jan 14;5(1):74-81. doi: 10.1016/j.bioactmat.2020.01.003. eCollection 2020 Mar.
Cardiovascular disease, ranging from congenital heart disease to adult myocardial infarction, is the leading cause of death worldwide. In pursuit of reliable cardiovascular regenerative medicine, human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), offer plenty of potential cell-based applications. HPSCs are capable of proliferating indefinitely in an undifferentiated state, and are also pluripotent, being able to differentiate into virtually any somatic cell types given specific stepwise cues, thus representing an unlimited source to generate functional cardiovascular cells for heart regeneration. Here we recapitulated current advances in developing efficient protocols to generate hPSC-derived cardiovascular cell lineages, including cardiomyocytes, endothelial cells, and epicardial cells. We also discussed applications of hPSC-derived cells in combination with compatible bioactive materials, promising trials of cell transplantation in animal models of myocardial infarction, and potential hurdles to bring us closer to the ultimate goal of cell-based heart repair.
心血管疾病,从先天性心脏病到成人心肌梗死,是全球范围内主要的死亡原因。为了寻求可靠的心血管再生医学,人类多能干细胞(hPSC),包括人类胚胎干细胞(hESC)和人类诱导多能干细胞(hiPSC),提供了大量基于细胞的潜在应用。hPSC能够在未分化状态下无限增殖,并且具有多能性,在特定的逐步诱导条件下能够分化为几乎任何体细胞类型,因此是生成用于心脏再生的功能性心血管细胞的无限来源。在此,我们概述了在开发高效方案以生成hPSC衍生的心血管细胞谱系方面的当前进展,这些谱系包括心肌细胞、内皮细胞和心外膜细胞。我们还讨论了hPSC衍生细胞与兼容生物活性材料的联合应用、在心肌梗死动物模型中进行细胞移植的前景试验以及使我们更接近基于细胞的心脏修复这一最终目标的潜在障碍。